Intralink-Spine, Inc. Expands Clinical Studies in Australia

LEXINGTON, KY, August 20, 2019

Intralink-Spine, Inc. announces the expansion of clinical trials in Australia for their patented medical device for the treatment of low back pain, called Réjuve™. “We’re pleased that Dr. Rosenberg and his staff are participating in the GEMS clinical study for low back pain.”, says Lyle Hawkins, CEO, of Intralink-Spine, Inc.

 

“The Réjuve treatment has the potential to fill the gap between non-operative treatments and surgery, which is why I’m excited to be involved in this study”, says Dr. Geoffrey Rosenberg, Orthopaedic Spine Surgeon.

 

 

Figure  SEQ Figure \* ARABIC 1(L to R) Dr. Geoffrey Rosenberg, Orthopaedic Spine Surgeon and Dr. Tom Hedman, Chairman & CSO, ILS

According to Hawkins, “We believe the Réjuve medical device, which structurally reinforces the native intervertebral disc itself, is going to be a better treatment option for many patients with low back pain. Réjuve has shown to have rapid results like an epidural steroid injection, but with potential long-term positive effects similar to a successful fusion.”

 

“The data from our early pilot study demonstrated exceptional results with regard to reducing or eliminating low back pain and disability. These benefits began within days of the initial procedure, demonstrating the immediate mechanical support provided by this device”, states Dr. Tom Hedman, Ph.D., the inventor and Adjunct Associate Professor in the F. Joseph Halcomb III, M.D. Department of Biomedical Engineering at the University of Kentucky. “We’re eager to begin gathering data from our clinical sites in Australia to further validate the unique benefits of the Réjuve device.”

 

© 2018 by Intralink-Spine Inc.  Réjuveis a registered trademark of Intralink-Spine, Inc.

Attention: Réjuve™ is not available for sale in the US, Canada, or EU. Clinical studies are pending.